Document is current
Any future updates will be listed below
-
Authors
Karjalainen, Joni
Sirkiä, Onni
Sirniö, Päivi
Elomaa, Hanna
Karjalainen, Henna
Äijälä, Ville K.
Kastinen, Meeri
Tapiainen, Vilja V.
Pohjanen, Vesa-Matti
Ahtiainen, Maarit
Helminen, Olli
Wirta, Erkki-Ville
Mattila, Taneli T.
Lindgren, Outi
Rintala, Jukka
Meriläinen, Sanna
Saarnio, Juha
Rautio, Tero
Seppälä, Toni T.
Böhm, Jan
Mecklin, Jukka-Pekka
Tuomisto, Anne
Mäkinen, Markus J.
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
-
Funding
Funding for this research was provided by:
Syöpäsäätiö (59-5619, 69-7354)
Emil Aaltosen Säätiö (220257P)
Sigrid Juséliuksen Säätiö (230229, 240241, 250264)
Finnish State Research Funding
University of Oulu
- License Information
-
More Information
Article History
Received: 5 July 2025
Revised: 28 September 2025
Accepted: 22 October 2025
First Online: 18 November 2025
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki. For cohort 2, the study was conducted under approval from the Regional medical research ethics committee of the Wellbeing services county of North Ostrobothnia (25/2002, 42/2005, 122/2009, 37/2020), Biobank Borealis (BB-2017_1012) and Fimea (FIMEA/2022/001941). For cohort 1, the study was conducted under approval from the Regional medical research ethics committee of the Wellbeing services county of Central Finland (Dnro 13U/2011, 1/2016, 8/2020, 2/2023), Central Finland Biobank (BB23-0172), and Fimea (Dnro FIMEA/2023/001573, 4/2023). In cohort 2, all participants gave written informed consent for the study. For cohort 1, the need to obtain informed consent from the study patients was waived (Dnro FIMEA/2023/001573, 4/2023).
: T. T. Seppälä reports consultation fees from Mehiläinen, Nouscom, Amgen, Orion, and Tillots Pharma, and having a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. Other authors declare that they have no conflicts of interest.
